Original Article

Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression

Yu-Lin Liu1, Ze-Xuan Yan2, Yu Xia1, Xiao-Ye Xie3, Kai Zhou2, Li-Li Xu1, Yan-Long Shi3, Qiang Wang1,3, Jing-Wang Bi3

1Clinical Laboratory, Navy 971 Hospital of PLA, Qingdao 266071, China; 2Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University, Chongqing 400038, China; 3Department of Oncology, 960 Hospital of PLA, Jinan 250031, China

Received September 29, 2019; Accepted February 7, 2020; Epub March 1, 2020; Published March 15, 2020

Abstract: Chemotherapy resistance is a major challenge for breast cancer treatment. It is necessary to elucidate the mechanisms of anthracycline resistance to develop new chemosensitizers for breast cancer. In this study, we explored the effects of ligustrazine (TMP) on reverting anthracycline resistance of breast cancer cells, as well as its related mechanisms. Clinical significance of fibrinogen gamma chain (FGG) expression was also analyzed in breast cancer tissues. We provided evidence that breast tumor cell derived FGG participated in anthracycline chemoresistance of breast cancer. Further, TMP reverted epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression. Meanwhile, the elimination of cancer stem cell was observed in TMP treated chemoresistant breast cancer cells. Clinical analysis demonstrated that patients with FGG expressing breast cancer showed a dramatically low response to anthracycline-based chemotherapy and poor survival. Our data collectively indicated that FGG was an independent detrimental factor for anthracycline based chemotherapy for breast cancer patients. TMP was a novel chemosensitizer for FGG-induced anthracycline chemoresistance in breast cancer treatment.

Keywords: Ligustrazine, fibrinogen gamma chain, breast cancer, JAK2/STAT3 pathway, anthracycline, chemotherapy resistance

Introduction

Therapeutic resistance is among the major challenges for breast cancer patients, which led to secondary metastasis and recurrence [1]. Genotoxic chemotherapy, including anthracycline, is an effective therapy in clinical practice. Epirubicin (EPI) is a principal approached anthracycline for breast cancer, which induced irreparable DNA damage for therapeutic effects [2]. However, intrinsic and secondary chemoresistance enhanced DNA repair to attenuate treatment response [3]. It is necessary to elucidate the regulation mechanisms of chemosensitivity and drug resistance to develop new chemosensitizers for breast cancer.

Ligustrazine (2,3,5,6-tetramethylpyrazine, TMP) is the major constituent of Rhizoma Chuanxiong. TMP exhibits a strong anti-oxidative activity, which was widely used in the treatment of cerebral and cardiac ischemic diseases for decades [4]. Recent studies indicated that TMP inhibited tumor metastasis and angiogenesis in vivo and in vitro by inducing cell apoptosis [5]. Previous studies also supported that TMP is an ameliorated effect on chemotherapy and reverting multidrug resistance [6, 7], which was a promising option for improving anthracycline-based chemosensitivity of breast cancer.

Accumulated evidences have suggested that plasma fibrinogen, an acute phase glycoprotein, is an important factor during cancer progression [8]. Fibrinogen is a large plasma protein composed of two sets of α, β and γ chains, which are encoded by independent genes [9]. Elevated pretreatment plasma fibrinogen is an independent detrimental predictor for patients with solid tumors [10]. Previous studies have
indicated that TMP attenuated blood hypercoagulable state by reducing fibrinogen levels, whereas the underlying molecular mechanisms have not been fully elucidated yet.

In this study, we provided evidence that tumor cells derived fibrinogen gamma chain (FGG) participated in anthracycline chemoresistance of breast cancer. Furthermore, TMP reverted EPI resistance by inhibiting Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling and decreasing FGG expression. Meanwhile, the elimination of cancer stem cells was also observed in TMP treated chemoresistant cancer cells. We demonstrated that patients with FGG expressing tumor showed a dramatically weak response to anthracycline-based chemotherapy. Our study collectively revealed TMP as a novel chemosensitizer for FGG-induced anthracycline chemoresistance in breast cancer treatment.

Materials and methods

Human primary tumor samples and clinical information

Breast cancer tissue samples and clinical document were collected from 405 patients were collected from 2006 to 2008. All patients received EPI-based chemotherapy after surgery. Clinical information and follow-up data, including preoperative serum fibrinogen levels, were collected and analyzed as previous report [11]. Criteria for anthracycline resistance were defined as recurrence, metastasis or death occurred within three years after anthracycline-based chemotherapy treatment.

Cell culture

Human breast cancer cell lines MCF7 and T47D were obtained from American Type Culture Collection (ATCC, MD). Both cells were grown in Dulbecco’s Modified Eagle Medium contained 1% penicillin and streptomycin, supplemented with 10% fetal bovine serum. EPI and TMP were obtained from Sigma-Aldrich (St Louis, MO). EPI resistant MCF7/EP cells were maintained in DMEM medium with gradient elevated EPI, which was continuous passage cultured for six months.

Cell infection

FGG plasmid was a gift from Gavin Wright (Addgene plasmid # 52031). Flag-tagged constitutively activated STAT3 (STAT3-C) plasmids were constructed as previous report [12]. Cell infection was performed with fresh lentivirus-containing medium supplemented with 8 μg/ml polybrene. The infection efficiency was confirmed with Western blot assays.

Western blot analysis

Western blot assays were performed as our previous study [13]. Primary antibodies, including FGG (ab217783), cleaved PARP (ab32064), Bcl-2 (ab32124), Bcl-XL (ab32370), JAK2 (ab108596), p-JAK2 (Y1007, 1008, ab32101), STA-T3 (ab119352), p-STAT3 (S727, ab32143), Oncostatin M (ab133748), anti-Flag (ab49763) and β-actin (ab8226) were purchased form Abcam (Cambridge, MA).

Quantitative real-time PCR (qRT-PCR)

qRT-PCR assays were performed as previous study [13]. RNAzol reagent were purchased form Invitrogen (Carlsbad, CA). The primers sequences of FGG: Forward 5’-GAATTTTGCC-TGGAAATGA-3’. Reverse 5’-ATCATCGCCAAAA-TCAAAG-3’.

Cell viability assays

Cell viability assays were performed as previous report [13]. Cell proliferation was measured with a WST-8 kit (Beyotime Inst Biotech, Shanghai, China) according to manufacturer’s instructions. The absorbance at 450 nm was measured with Multiskan Spectrum 1500 (Thermo Scientific, PA). IC50 (50% cell growth inhibition) was analyzed with Prism GraphPad 8.0 (GraphPad Inc., La Jolla, CA).

Colony formation assays

Single-cell suspensions were cultured in DMEM medium with indicated TMP or equal vehicle combined with 2.2 μg/mL EPI in 12-well plates (200 cells/well) for two weeks. Cell clones were fixed and stained with crystal violet. Clones with more than 50 cells were counted with microscope. Three independent assays were performed.

Xenografts

Subcutaneous xenografts were established as our previous study [13]. Totally 10⁶ breast cancer cells were subcutaneous planted until 100 mm³. The mice were randomly separated into
two groups for TMP treatment. TMP (100 mg/kg/d) or vehicle control was administrated intraperitoneally every other day. The animal experiments were conformed to the Declaration of Helsinki (revised in Fortaleza, Brazil, October 2013) and approved by the Ethics Committee of Animal Care and Use Committee of Army Medical University.

Cell apoptosis analysis

Cell apoptosis was measured with Annexin V-FITC Apoptosis Detection Kit (Beyotime Ins. Shanghai, China). Typically, harvested cells were stained with Annexin V and propidium iodide in 100 μl binding buffer for 30 min in dark room. Then tested with FACS Aria II flow cytometer (BD Biosciences, NJ).

Caspase-3 activity measurement

Caspase-3 Activity Assay Kit (Beyotime Ins. Biotec, China) was used to determine Caspase-3 activity. TMP treated cells were lysed and incubated with 200 μM DEVD-pNA substrate at 37°C for 1 h. Then measured the absorbance at 405 nm with microplate reader (Thermo Electron Corporation, MA).

Mammosphere formation assays

Single-cell suspension of MCF7/EP cells (500 cells/well) were seeded in ultralow attachment plate (Corning Inc, Corning, NY) with conditioned DMEM/F-12 medium as previous studies [13]. Mammospheres were counted manually after 7 days culture. Then mammosphere cells were collected and suspended for secondary sphere formation.

Flow cytometry for ALDH1 percentage

Flowcytometry analysis for ALDH1 was measured with The ALDEFLUOR kit (StemCell Technologies, Durham, NC) in FACS Aria II flow cytometer (BD Biosciences, San Jose, CA) as previous study [13]. Then analyzed with FlowJo software (Tree Star, San Carlos, CA).

Immunohistochemical staining (IHC)

Human tumor and xenograft specimens were prepared for sections. IHC staining was conducted with Ventana Discovery XT automated staining system (Ventana Medical Systems, Inc., Tucson, AZ) following the manufacturers’ protocols as previous report [14]. FGG (ab217783), Bcl-2 (ab32124), Ki67 (ab92742), ALDH1A1 (ab215996) and p-STAT3 (S727, ab32143) primary antibody was purchased from Abcam.

Statistical analysis

Statistical analyses were performed with IBM SPSS statistics 24.0 (IBM, Chicago, IL), Graphpad Prism 8.0 (GraphPad Software, Inc., La Jolla, CA). Data from at least three independent experiments are described as the means ± standard deviation (SD). Student's t-tests were used to compare the differences between groups. Fisher's exact test was used to assess the clinical correlation. Cox proportional-hazards regression was used for univariate and multivariate analysis. Kaplan-Meier analysis and log-rank test were used for prognostic values. All statistical tests were two-sided, and P ≤ 0.05 was considered statistically significant.

Results

Increased FGG levels are correlated with anthracycline chemotherapy resistance in breast cancer

We evaluated the correlation of serum fibrinogen levels and chemotherapy response with anthracycline based chemotherapy in human breast cancer. Preoperative serum fibrinogen levels were estimated in 405 breast cancer patients that received anthracycline chemotherapy. Our results indicated that the patients with high preoperative fibrinogen levels (> 3.00 g/L) exhibited high percentage of anthracycline chemotherapy resistance than those with low fibrinogen levels (36.84% vs. 12.65%. P < 0.001. Figure 1A). Moreover, the patients resistant to anthracycline based chemotherapy showed higher fibrinogen levels than those effective ones (P < 0.001. Figure 1B). Further analysis was performed for the tumor-derived fibrinogen chains with TCGA data (1088 cases), including FGA, FGB and FGG. The results supported that breast tumor tissues were important source for plasm fibrinogen. Totally, 968 tumor specimens have at least one chain of fibrinogen mRNA expression (89.0%). Among them, 439 specimens were positive for FGA mRNA (40.3%), 675 for FGB (62.0%) and 678
Ligustrazine reverts breast cancer anthracycline chemoresistance

Figure 1. Increased FGG levels are correlated with anthracycline chemotherapy resistance in breast cancer. A. Preoperative serum fibrinogen levels were collected from 405 breast cancer patients. The patients with high fibrinogen levels (> 3.00 g/L) showed higher percentage of anthracycline chemotherapy resistance than low fibrinogen patients (P < 0.001). B. The anthracycline based chemotherapy resistant patients showed higher fibrinogen levels than those effective ones (P < 0.001). C. The mRNA levels of FGA, FGB and FGG, three isolate chains of fibrinogen, were analyzed in 1088 breast cancer tissues from TCGA data. D. The comparation of disease progression was analyzed between FGG-positive patients and negative patients with TCGA data. Increased disease progression was observed in the patients with positive FGG mRNA expression. P = 0.005. E. The protein level of FGG were measured in EPI resistant MCF7 cells (MCF7/EP vs. parental) with Western blot assays. β-actin was used as loading control. F. Comparison of FGG mRNA levels between MCF7/EP vs. parental cells, which was determined by qRT-PCR assays. β-actin was used as control.

for FGG (62.3%) (Figure 1C). Furthermore, increased FGG mRNA expression was correlated with increased disease progression after surgery (Figure 1D). Based on these results, an EPI resistant MCF7 cells, MCF7/EP, was prepared for the correlation of FGG and anthracycline resistance. Elevated FGG protein levels were observed in MCF7/EP cells than parental ones by Western blot assays (Figure 1E). The mRNA abundance was consistent with the protein levels (Figure 1F), indicating the promising role of FGG in anthracycline-based chemotherapy resistance of breast cancer cells.

FGG promotes breast cancer cell survival and proliferation with anthracycline treatment in vitro and in vivo

Exogenous expression of FGG in breast cancer cell lines were confirmed by immunoblotting assays (Figure 2A). Notably, MCF7-FGG cells showed significant higher IC50 under EPI treatment than control cells (IC50: 9.32 μM vs. 3.23 μM, P < 0.01, Figure 2B). Furthermore, CCK-8 assays showed that cell viability was significantly increased in MCF7-FGG cells than control ones with 3.0 μM EPI treatment (Figure 2C). Increased cell viability was observed in FGG overexpressed T47D cells (Figure 2D). Our results also indicated that cell clone formation of FGG overexpressing cells was increased than control cells with EPI treatment (Figure 2E, 2F). More importantly, xenografts of infected MCF7 cells were subcutaneously planted in node mice, and then, we treated the mice with EPI medium (5 mg/kg EPI per 2 days). The xenografts of MCF7-FGG cells showed significantly increased tumor volume and weight than control cells (Figure 2G, 2H). These data suggested that FGG was involved in anthracycline chemotherapy resistance of breast cancer.

TMP reduces FGG expression and reverses anthracycline resistance of breast cancer cells

TMP was used as a fibrinogen regulator to ameliorate hypercoagulable state [15]. Then, we evaluated TMP as a chemosensitizer in anthracycline resistant breast cancer cells. As expected, TMP treatment significantly reduced the expression levels of FGG in a dose-dependent
Ligustrazine reverts breast cancer anthracycline chemoresistance

Figure 2. FGG promotes breast cancer cell survival and proliferation with anthracycline treatment in vitro and in vivo. A. FGG overexpression was performed with MCF7 and T47D cells. FGG protein levels of infected human breast cancer cells were measured with Western blot assays. β-actin was used as loading control. B. MCF7-FGG/-vector cells were treated with a gradient concentration of EPI. CCK-8 assays were performed to determine the IC50 of infected cells, which was analyzed with a nonlinear regression model with GraphPad Prism. C and D. Cell viability was measured in MCF7-FGG and T47D-FGG cells and control with 3.0 μM EPI treatment for 72 hours. E. Cell clone formation assays were performed with infected MCF7 and T47D cells, which showed increased cell clones than corresponding control cells. F. Representative images of clone formation of infected MCF7 and T47D cells, which were captured after 14 days culture. G. Xenografts of infected MCF7 cells were planted and treated with EPI medium (5 mg/kg EPI once per 3 days) when the volume was about 100 mm³. Tumor volume was recorded with the mean volumes of tumor size in the indicated day. H. Xenografts were harvested and imagined after 15 days treatment. Bar = 1 cm. The tumor weights were compared between two groups. Data represent the means ± SD. *P < 0.05.

manner (Figure 3A). Moreover, TMP treatment increased the sensitivity of EPI resistant MCF7 cells, as evidenced by decreased cell viability in combined treatment with EPI and TMP (100 μM) (Figure 3B). However, no significant inhibition of cell viability was observed in only TMP treated MCF7/EP cells (Figure S1A). Flow cytometry analysis was further performed to measure the percentage of apoptotic cells with TMP treatment. Compared to vehicle control group, TMP treatment significantly increased early and late apoptosis percentages of MCF7/EP cells (P < 0.01. Figure 3C, 3D). Correspondingly, increased activities of caspase 3 were observed in combined EPI and TMP treated MCF7/EP cells (P < 0.01. Figure 3E). Meanwhile no significant changes were observed in only TMP treatment (Figure S1B). Furthermore, the pro-apoptotic effects of TMP were also indicated by the increased cleaved PARP, and decreased Bcl-2 and bcl-xl (Figure 3F). Next, we evaluated the therapeutic efficacy of TMP on tumor growth of breast cancer in vivo. MCF7/EP cells were subcutaneously implanted into six-week-old athymic nude mice in fat pad. Then, the mice were treated with TMP and EPI in an intravenous infusion (5 mg/kg). Marked inhibitory potency was observed on tumor growth in combined TMP treatment group (Figure 3G). The mean tumor volume and weight of TMP-treated group were both significantly lower than the control group after 15 days treatment (Figure 3H). Further analysis indicated that only TMP treatment failed to inhibit tumor growth in vivo (Figure S1C). Collectively, these results indicated that TMP reversed anthracycline resistance of breast cancer cells.
Ligustrazine reverts breast cancer anthracycline chemoresistance

Figure 3. TMP reduces FGG expression and reverses anthracycline resistance of breast cancer cells. (A) MCF7/EP cells were treated with a gradient concentration of TMP for 48 h. The mRNA levels of FGG were measured with qRT-PCR assays. β-actin was used as control. (B) Cell viability of MCF7/EP cells were detected with CCK-8 assays. MCF7/EP cells were treated with combined EPI (3 μM) and indicated concentration of TMP for 60 h. (C) MCF7/EP cell apoptosis were measured in different treatment: EPI (3 μM) + vehicle, EPI (3 μM) + TMP (50 or 100 μM). Cell apoptosis was analyzed with flow cytometry by Propidium iodine and Annexin V staining. (D) Statistics of MCF7/EP cell apoptosis in combined treatment or EPI only groups as described in (C). (E) Activity of caspase-3 was measured by pNA concentrations with Caspase-3 Activity Assay Kit. (F) Apoptosis related proteins (cleaved PARP, Bcl-2 and Bcl-xL) in TMP treated MCF7/EP cells were analyzed with Western blot assays. β-actin was used as loading control. (G) Xenografts growth of MCF7/EP cells with the treatment of EPI with/without TMP. Tumor volume was recorded after
Ligustrazine reverts breast cancer anthracycline chemoresistance

945 Am J Cancer Res 2020;10(3):939-952

TMP eliminates cancer stem cells of anthracycline resistant breast cancer cells

Further investigation was performed to study stemness related characteristics of TMP treated breast cancer cells. Suspended tumor spheres were established with the help of non-adhesive suspension culture system. Anthracycline resistant MCF7/EP cells, formed floating spherical colonies within 7 days, whereas TMP treatment significantly reduced the volume of mammospheres (Figure 4A). More importantly, decreased number of mammospheres were observed with TMP treatment (Figure 4B). Secondary spheroids were also cultured and calculated to confirm that TMP treatment eliminated breast cancer stem cell (Figure 4A, 4B). More importantly, decreased percentage of breast CSCs (ALDH1<sup>high</sup>) was also observed under the condition of TMP treatment by flowcytometry analysis (Figure 4C). Next, FACS sorted ALDH1<sup>high</sup> cells were treated with different concentrations of TMP for 48 h, indicating TMP inhibited the proliferation of breast CSCs (ALDH1<sup>high</sup> cells subpopulation) (Figure 4D). Next, we evaluated the effect of TMP on tumorigenesis of breast cancer in vivo. MCF7/EP cells were treated with TMP or vehicle for 48 hours, then dissociated and implanted subcutaneously into the fat pad of nude mice. The results showed decreased tumorigenicity of TMP treated cells than control cells (Figure 4E, 4F). Furthermore, IHC staining was performed with the xenografts of TMP treated MCF7/EP cells, and the results showed that TMP treatment decreased bcl-2, ki67, ALDH1A1 and p-STAT3 expression in xenografts (Figure 4G). Taken together, these data suggest that TMP is an effective agent in inhibiting self-renewal capacity of breast cancer cells.

TMP reduces FGG expression by JAK2/STAT3 pathway inhibition in breast cancer cells

Based on the above results, we studied the underlying mechanism of TMP in reversing EPI resistance. CCK8 assays showed that combined treatment of TMP did not increase the toxicity of EPI for MCF7-FGG cells (Figure 5A). Moreover, there is no significant change in the percentage of ALDH1<sup>high</sup> cells in FGG overexpressing patients under TMP treatment (Figure 5B). These results supported a crucial role of FGG in synergistic effects of TMP in EPI based chemotherapy of breast cancer.

Previous studies indicated that EPI resistant was correlated with JAK2/STAT3 signal activation [16]. We explored their correlation with elevated FGG expression in anthracycline-resistant breast cancer cells. Immunoblotting assays were performed for the status of JAK2/STAT3 signal activation of TMP treated MCF7/EP cells, and the results showed that STAT3 and JAK2 phosphorylation and Oncostatin M level was increased in EPI treated MCF7/EP cells, whereas 50 μM TMP treatment decreased their expression (Figure 5C). However, we did not observe significant change in STAT3 and JAK2 phosphorylation levels between FGG overexpressing cells and corresponding control (Figure 5D). Therefore, these results suggested that TMP inhibited JAK2/STAT3 signaling to decrease FGG expression.

To further confirm the role of STAT3 activation in FGG regulation, parental MCF7 cells were infected with a constitutively activated STAT3 construct (STAT3-C). Immunoblotting assays showed increased FGG protein level in STAT3-C infected cells, which was also not attenuated with TMP treatment (Figure 5E). Flowcytometry assays showed that combined EPI and TMP treatment failed to enhance cell apoptosis of MCF7-STAT3-C cells (Figure 5F, 5G). Moreover, STAT3-C-overexpressing cells also significantly abrogated cell proliferation inhibition effects of TMP treatment, which was confirmed with CCK-8 assays (Figure 5H). These results supported that JAK2/STAT3 signaling inhibition is involved in TMP treatment induced FGG down-regulation. JAK2/STAT3 blockage by TMP was a valuable chemosensitizer for breast cancer therapy.

Elevated FGG expression in tumor tissue predicts poor survival estimation of breast cancer

IHC staining for FGG was performed with 405 breast cancer specimens. Positive FGG expression was detected in 42 breast cancer specimens (56.76%), which was arranged in cytoplasm and tumor stroma (Figure 6A). Notably,
Figure 4. TMP eliminates cancer stem cells of anthracycline resistant breast cancer cells. A. Single MCF7/EP cells were consecutively planted in suspension culture system, which were treated with 50 μM TMP for 7 days. Representative images of mammospheres were captured at the 7th day. B. Mammosphere number was counted and compared between different groups at the 7th day. C. MCF7/EP cells was treated with different concentration of TMP for 48 h. Flowcytometry analysis was performed for the ALDH1high percentage of the cells with different treatment. D. MCF7/EP-ALDH1high cells were sorted for cell viability inhibition analysis. FACS sorted cells were treated
Ligustrazine reverts breast cancer anthracycline chemoresistance

with combined EPI and indicated concentration of TMP for 48 h. Data represent the means ± SD. *P < 0.01. E and F. MCF7/EP cells were treated with combined EPI and TMP (50 μM) or only EPI for 48 hours. Serial dilution of cells were implanted into the mammary fat pads of nude mice for xenografts (n = 6 each group). Tumor initiation numbers were analyzed with Extreme Limiting Dilution Analysis. G. IHC staining of Bcl-2, Ki67, ALDH1A1 and p-STAT3 were performed with the xenografts of TMP treated MCF7/EP cells. Scale bars, 20 μm.
Ligustrazine reverts breast cancer anthracycline chemoresistance

Increased serum fibrinogen levels were observed in FGG positive group than negative ones (Figure 6B). Further analysis indicated a positive correlation between FGG expression and lymph node metastasis (P < 0.001) and elevated histological grade (P < 0.001) (Table 1). However, no significant correlation was observed between FGG expression and other clinical variables, including age, tumor location, clinical stage and the expression of ER, PR, HER2 (P > 0.05, Table 1).

The median followed-up period of the patients in this study was 39.94 months (range: 1.64-63.39 months). Disease progression was observed in 88 patients (21.73%) during followup periods. Kaplan-Meier analysis showed significantly worse overall survival (OS) and disease-free survival (DFS) in FGG positive group than negative one (P < 0.001, respectively. Figure 6C, 6D). Cox regression analysis also indicated an independent prognostic significance of FGG with univariate analysis (OS: HR = 7.137, 95% CI: 4.196-12.141, P < 0.001; DFS: HR = 6.080, 95% CI: 3.932-9.401, P < 0.001, Table 2). Multivariate analysis also showed that FGG expression was a detrimental factor for both OS and DFS (OS: HR = 5.862, 95% CI: 3.566-9.634, P < 0.001. Table 2). Furthermore, Kaplan-Meier analysis of TCGA breast cases also supported that ele-
Ligustrazine reverts breast cancer anthracycline chemoresistance

Table 1. Relationship between Clinical Characteristics and FGG Expression

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number (%)</th>
<th>FGG expression</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Total</td>
<td>405</td>
<td>104 (25.7%)</td>
<td>301 (74.3%)</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50</td>
<td>241 (59.5%)</td>
<td>59 (14.6%)</td>
<td>182 (44.9%)</td>
</tr>
<tr>
<td>≥ 50</td>
<td>164 (40.5%)</td>
<td>45 (11.1%)</td>
<td>119 (29.4%)</td>
</tr>
<tr>
<td>Tumor size, cm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 2</td>
<td>167 (41.2%)</td>
<td>45 (11.1%)</td>
<td>122 (30.1%)</td>
</tr>
<tr>
<td>2-5</td>
<td>202 (49.9%)</td>
<td>47 (11.6%)</td>
<td>155 (38.3%)</td>
</tr>
<tr>
<td>≥ 5</td>
<td>36 (8.9%)</td>
<td>12 (3.0%)</td>
<td>24 (5.9%)</td>
</tr>
<tr>
<td>Histological status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>122 (30.1%)</td>
<td>14 (3.5%)</td>
<td>108 (26.7%)</td>
</tr>
<tr>
<td>II</td>
<td>184 (45.4%)</td>
<td>37 (9.1%)</td>
<td>147 (36.3%)</td>
</tr>
<tr>
<td>III</td>
<td>99 (24.4%)</td>
<td>53 (13.1%)</td>
<td>46 (11.4%)</td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>229 (56.5%)</td>
<td>28 (6.9%)</td>
<td>201 (49.6%)</td>
</tr>
<tr>
<td>1-3</td>
<td>107 (26.4%)</td>
<td>29 (7.2%)</td>
<td>78 (19.3%)</td>
</tr>
<tr>
<td>≥ 4</td>
<td>69 (17.0%)</td>
<td>47 (11.6%)</td>
<td>22 (5.4%)</td>
</tr>
<tr>
<td>ER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>253 (62.5%)</td>
<td>63 (15.6%)</td>
<td>190 (46.9%)</td>
</tr>
<tr>
<td>Negative</td>
<td>152 (37.5%)</td>
<td>41 (10.1%)</td>
<td>111 (27.4%)</td>
</tr>
<tr>
<td>PR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>311 (76.8%)</td>
<td>52 (12.8%)</td>
<td>159 (39.3%)</td>
</tr>
<tr>
<td>Negative</td>
<td>194 (47.9%)</td>
<td>52 (12.8%)</td>
<td>142 (35.1%)</td>
</tr>
<tr>
<td>HER2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>104 (25.7%)</td>
<td>26 (6.4%)</td>
<td>78 (19.3%)</td>
</tr>
<tr>
<td>Negative</td>
<td>301 (74.3%)</td>
<td>78 (19.3%)</td>
<td>223 (55.1%)</td>
</tr>
</tbody>
</table>

CI = confidence interval; HR = hazard ratios. The variables were compared in the following ways: Age, ≥ 50 years vs. < 50 years; FGG expression, positive vs. negative; size, > 2 cm vs. < 2 cm; Stage, III-IV vs. I-II; Grade, G3-4 vs. G1-2; Lymph, Yes vs. no; ER, PR, HER2, yes vs. no.

Table 2. Univariate and Multivariate Analyses of FGG expression in Disease-Free Survival and Overall Survival

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall Survival</th>
<th>Disease-Free Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Univariate</td>
<td>N = 405</td>
<td>N = 405</td>
</tr>
<tr>
<td>FGG</td>
<td>7.137</td>
<td>4.196-12.141</td>
</tr>
<tr>
<td>Multivariate</td>
<td>N = 405</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.854</td>
<td>0.494-1.478</td>
</tr>
<tr>
<td>Size</td>
<td>1.221</td>
<td>0.664-2.245</td>
</tr>
<tr>
<td>Stage</td>
<td>0.989</td>
<td>0.667-1.467</td>
</tr>
<tr>
<td>Grade</td>
<td>0.399</td>
<td>0.195-0.816</td>
</tr>
<tr>
<td>Lymph</td>
<td>1.368</td>
<td>0.721-2.596</td>
</tr>
<tr>
<td>ER</td>
<td>0.716</td>
<td>0.344-1.490</td>
</tr>
<tr>
<td>PR</td>
<td>0.848</td>
<td>0.424-1.694</td>
</tr>
<tr>
<td>HER2</td>
<td>1.132</td>
<td>0.616-2.080</td>
</tr>
<tr>
<td>FGG</td>
<td>8.641</td>
<td>4.738-15.758</td>
</tr>
</tbody>
</table>

CI = confidence interval; HR = hazard ratios. The variables were compared in the following ways: Age, ≥ 50 years vs. < 50 years; FGG expression, positive vs. negative; size, > 2 cm vs. < 2 cm; Stage, III-IV vs. I-II; Grade, G3-4 vs. G1-2; Lymph, Yes vs. no; ER, PR, HER2, yes vs. no.

Discussion

Based on the above results, we proposed that FGG participates in modulating anthracycline chemotherapy sensitivity of breast cancer cells. Furthermore, TMP reverted EPI resistance by suppressing JAK2/STAT3 signaling and FGG expression, as a novel chemosensitizer for anthracycline chemoresistance in breast cancer treatment.

Anthracycline is an effective drug for breast cancer treatment, which is recommended as the first-line adjuvant chemotherapy [17]. However, metastasis and recurrence because of chemotherapy resistance are still the major cause for tumor related death [18]. Therefore, it is of particular importance to determine the core genes involved in chemotherapy resistance, and to study its effect on drug susceptibility to neoadjuvant chemotherapy. In this study, we explored the function of tumor cell derived fibrinogen expression, especially FGG, and provided evidences that tumor cell derived FGG participates in anthracycline chemore-
Ligustrazine reverts breast cancer anthracycline chemoresistance

Resistance of breast cancer. Breast cancer cell with elevated FGG expression showed a survival advantage in anthracycline treatment. Further randomized controlled trials are necessary to clinically assess the optimized regimens for the cancer patients with increased fibrinogen levels.

Microenvironmental factors, such as hypercoagulable states, have been reported to influence the therapeutic response of local tumors [19, 20]. Tumor cells also participate in the formation of hypercoagulable microenvironment, including elevated fibrinogen chain expression [10]. Fibrinogen matrix acts as a reservoir for secreted growth factors to facilitate tumor growth, angiogenesis, and distant metastasis [21, 22]. Abnormal fibrinogen levels are at least partially caused by tumor cells in local microenvironment [23]. In our previous study, we found that serum fibrinogen levels were correlated with poor response to Trastuzumab treatment in breast cancer patients [24]. Here, imbalances in the intracellular levels of different fibrinogen chains, α, β, and γ chains, were also observed in tumor cells, which was consistent with hepatocytes and hepatoma cells as previous reports [25]. Aberrant FGG expression was observed in a large proportion of breast cancer specimens. In particular, an excess amount of FGG expression was identified in tumor cells and plasma under anthracycline chemoresistance. Elevated FGG expression in cancerous tissues induces chemoresistance of breast cancer. We performed clinical analysis to study the prognostic role of FGG in chemotherapy and survival estimation. We identified FGG expression in tumors was an independent detrimental factor for breast cancer patients. Other study indicated a significant correlation between FGG and C-reaction protein [26], indicating its potential function in inflammation [27]. Further analysis is still needed for the function of microenvironment in breast cancer progression, including fibrinogen-dependent inflammatory response in chemotherapy resistance.

Accumulated evidences supported that traditional Chinese medicine was an inexhaustible novel drug treasure. TMP is a major bioactive component of traditional Chinese medicine Rhizoma Chuanxiong, which has been widely used in cardiovascular and cerebrovascular diseases management [15, 28]. Recent studies also indicated its anticancer activity on melanoma metastasis and angiogenesis [5]. Increased tumor cell apoptosis was observed in TMP treated cells, especially multidrug resistant malignant cells [29, 30]. We found that the introduction of TMP to anthracycline increased chemotherapy cytotoxicity. More importantly, TMP reverted EPI resistance of breast cancer. Our results supported TMP as a compound to enhance the chemotherapy efficiency [31, 32].

Previous studies indicated that TMP increased intracellular reactive oxygen species accumulation to enhance tumor cell apoptosis [33]. Furthermore, TMP inhibited ATP-binding cassette transporter to revert multidrug resistance [34, 35]. In this study, we provided evidence that JAK2/STAT3 signaling activation and elevated FGG expression also participated in EPI resistance. JAK2/STAT3 signaling activation plays an important role in fundamental cellular processes, including tumorigenesis, cell proliferation and therapeutic resistance [36-38]. Especially, aberrant STAT3 signaling activation was observed in EPI resistant breast cancer cells [39, 40]. Disruption of STAT3 signaling by TMP reduced FGG expression and viability of EPI resistant cancer cells. Notably, JAK2/STAT3 inhibition by TMP supported a crucial role of this pathway for stemness maintaining of cancer stem cells [30]. Our results supported TMP as a chemosensitizer for breast cancer chemotherapy, especially anthracycline based chemotherapy. Unfortunately, the toxicity of TMP showed cumulative effects in vivo to some extent [15]. Thus, further modification of TMP is still needed to improve its therapeutic potency.

In conclusion, our study collectively identified FGG was an independent detrimental factor for anthracycline based chemotherapy in breast cancer patients. TMP is a novel chemosensitizer for FGG-induced anthracycline chemoresistance in breast cancer treatment.

Acknowledgements

This research was supported by grants from National Natural Science Foundation of China (81502283, 81972793), Shinan District Science and Technology Plan, Qingdao (2016-3-020-YY and 2018-4-026-YY), Shandong province Medical Health Science and Technology Project (2018WS447), Qingdao Science and Technology Program for Benefiting People Special Project 2019 (19-6-1-25-nsh), 2019 Annual Medical Scientific Research Guidance Plan of Qingdao (2019-WJZD170).
Ligustrazine reverts breast cancer anthracycline chemoresistance

Disclosure of conflict of interest

None.

Abbreviations

EPI, Epirubicin; TMP, Ligustrazine (2,3,5,6-tetramethylpyrazine); FGG, fibrinogen gamma chain; JAK, Janus kinase; STAT, signal transducer and activator of transcription; ATCC, American Type Culture Collection; CCK-8, Cell counting Kit-8; qRT-PCR, Quantitative real-time RT-PCR; IHC, Immunohistochemistry; SD, standard deviation; STAT3-C, constitutively activated STAT3; OS, Overall survival; DFS, Disease-Free Survival; ER, estrogen receptor; PR, progesterone receptor; HER2, Human epidermal growth factor receptor 2; CI, confidence interval; HR, hazard ratios.

Address correspondence to: Jing-Wang Bi and Qiang Wang, Department of Oncology, 960 Hospital of PLA, 25# Shifan Road, Tianqiao District, Jinan 250031, China. E-mail: jingwangbi@outlook.com (JWB); wangling401@gmail.com (QW)

References

Ligustrazine reverts breast cancer anthracycline chemoresistance


Figure S1. TMP treatment in anthracycline resistant breast cancer cells. A. Cell viability of MCF7/EP cells were detected with CCK-8 assays. MCF7/EP cells were treated with vehicle or indicated concentration of TMP for 60 h. B. Activity of caspase-3 was measured by pNA concentrations with Caspase-3 Activity Assay Kit. C. Xenografts growth of MCF7/EP cells with the treatment of vehicle or TMP. Tumor volume was recorded after the treatment with the mean tumor volumes in the indicated day. Xenografts were harvested and imagined after 21 days’ treatment. Bar = 1 cm. Data represent the means ± SD.